Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Carcinoma, Hepatocellular 28Breast Neoplasms 26Small Cell Lung Carcinoma 20Lung Neoplasms 20Triple Negative Breast Neoplasms 18Urinary Bladder Neoplasms 17Neoplasms 16Carcinoma, Transitional Cell 16Neoplasm Metastasis 15Melanoma 15Colorectal Neoplasms 15Uterine Cervical Neoplasms 11Carcinoma, Renal Cell 10Stomach Neoplasms 7Recurrence 7Head and Neck Neoplasms 7Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma, Malignant 5Liver Neoplasms 5Carcinoma, Squamous Cell 5Ovarian Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Biliary Tract Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Thoracic Neoplasms 3

Interventions

Cisplatin 18Radiotherapy 9Gemcitabine 8Fluorouracil 8Docetaxel 7Paclitaxel 6Carboplatin 5Capecitabine 5Radiotherapy, Intensity-Modulated 4Oxaliplatin 4Nivolumab 3Endostatins 3Bevacizumab 3toripalimab 2spartalizumab 2pembrolizumab 2endostar protein 2apatinib 2Cetuximab 2Celecoxib 2triethanolamine 1sintilimab 1regramostim 1penpulimab 1infigratinib 1fluzoparib 1cc-486 1camrelizumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Neoplasms × atezolizumab × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡